HIV and the Seroprevalence of SARS-CoV-2

Importance Healthy HIV-positive insurance applicants have a similar risk of infection and produce a similar antibody response as HIV-negative applicants infected with COVID-19. Objective Study the seroprevalence and immune response to COVID-19 in healthy HIV-positive life insurance applicants. Design From January 2020 to March 2021, we examined the seroprevalence of COVID-19 in all HIV-positive applicants. Antibody level in 340 age and sex matched COVID-19 positive applicants, 170 HIV-positive and 170 HIV negative, are compared. The data was de-identified of all personal information and separated by month, age and sex. Participants Self-reported healthy HIV positive life insurance applicants were tested for antibodies to COVID-19.